![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
PRESCRIBING PATTERN OF ANTIDIABETIC DRUGS FOR TYPE 2 DIABETIC IN TERTIARY CARE TEACHING HOSPITAL
Nithin Baby*, Cyril Tom, Asha Ann Joseph, Ann Abraham, Basavaraj K. Nanjwade
ABSTRACT The current objective of study is to screen the prescription trends in type II diabetes mellitus patients. Assess glycemic control and cardiac parameters in patients with type II diabetes mellitus. Promoting cost effective treatment & assured rational use of medications. In this study, 200 cases were collected in which determines OADDS therapy were administered for type II DM patients rules out generic or essential drug prescribing. The study was simple prospective observational study which was carried out for a period of six months. The patients were collected based on inclusion and exclusion criteria. Here we evaluated the type of therapy mostly administered to patients whether single or in combination. The gender, age of the patient, type of anaesthetic and type of surgery performed were reported. The results were analyzed. In this study 200 cases involving OADDS administration were included. Table 1 gives demographic characteristics of patients to whom OADDs were administered based on age and gender. Maximum numbers of patients were in the age group of above 60years (95.70%) and among 200 cases, males constituted 106 (57%) and females94 (47%). Out of 200 patients 112 patients (66.27%) patients were found suffering with co morbid concurrent illness hypertension followed by cardio complications associated (HTN-IHD, HTN-CAD, OTHERCOMORBIDITIES). The percentage of patients on anti-diabetic monotherapy (99, 49.5%), dual-therapy (79, 39.5%), and triple therapy (22, 11%). The study reveals that human insulin preparation is the most prescribe in 53 patients (26.5%). Among the drug combination 36 patients received Glimepiride + Metformin combination (18.12%) followed by insulin + metformin (10, 5%), insulin + glipizide (3,1.5%) insulin + glimepride (4, 2%) metformin + glipizide ( 14, 7%) metformin + sitagliptin (4,2%). Respectively 5 triple therapy combinations of OADDs were analyzed as such insulin + metformin + glimepride (3, 1.5%), glimepride + metformin + pioglitazone (3, 1.5%) insulin + metformin + sitagliptin (2, 1%) insulin + metformin + glipizide (14, 7%). Clinical effectiveness of therapy is influenced by prescriber agent selection and therapy changes as well patient’s adherence with prescribed drug regimens. Keywords: Antidiabetic drugs; Type II diabetes mellitus; anti-diabetic monotherapy; dual-therapy; triple therapy. [Download Article] [Download Certifiate] |